Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Atara Biotherapeutics, Inc. - Common Stock
(NQ:
ATRA
)
11.40
+1.47 (+14.80%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atara Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 13, 2022
Good morning, investors! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
This Healthcare Stock is Down By More Than 50%: Here's 25 Stocks Moving Premarket
July 13, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 12, 2022
Gainers Guardant Health (NASDAQ:GH) stock rose 14.8% to $55.23 during Tuesday's after-market session. The market value of their outstanding shares is at $5.6 billion.
Via
Benzinga
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
May 23, 2022
Via
Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
July 13, 2022
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Via
Benzinga
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
July 12, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
July 08, 2022
Via
Benzinga
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
July 06, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
June 30, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
Via
Benzinga
Dow Jumps 150 Points; Icosavax Shares Plunge
June 29, 2022
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday.
Via
Benzinga
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress
June 04, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Where Atara Biotherapeutics Stands With Analysts
May 24, 2022
Over the past 3 months, 4 analysts have published their opinion on Atara Biotherapeutics (NASDAQ:ATRA) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Atara Biotherapeutics: Here's What You Need To Know
May 23, 2022
HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00. Shares of Atara Biotherapeutics are trading down 3.1%...
Via
Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
May 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 20, 2022
Via
Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
May 20, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
May 19, 2022
Gainers Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's market cap stands at $330.1 million.
Via
Benzinga
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
May 19, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
May 10, 2022
Upgrades
Via
Benzinga
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
May 05, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Earnings Preview
May 04, 2022
Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Atara...
Via
Benzinga
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 29, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
April 28, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 22, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
April 05, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.